SCHEMBL5887461

SCHEMBL5887461

COc1ccc(C2=C(Cl)[CH]CC=C2c2ccc(Cl)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
BACE1 P56817 1/20 0.38
ALOX5 P09917 1/20 0.37
GLA P06280 1/20 0.37
GSK3B P49841 2/20 0.36
ME2 P23368 1/20 0.36
ME1 P48163 1/20 0.36
ME3 Q16798 1/20 0.36
ALKBH3 Q96Q83 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
KCNA5 P22460 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887086 0.90 ALKBH3 (0.46) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887257 0.87 ALKBH3 (0.40) NPC1RAB9ASMN1; SMN2HPGDHSP90AA1
SCHEMBL5887297 0.87 NPC1 (0.38) NPC1RAB9ASMN1; SMN2HPGDHSP90AA1
SCHEMBL5887165 0.85 NPC1 (0.38) NPC1RAB9ASMN1; SMN2HPGDHSP90AA1
SCHEMBL4013085 0.83 CYP2D6 (0.38) NPC1RAB9AHPGD
SCHEMBL5887097 0.79 ALOX5 (0.40) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887134 0.78 ALOX5 (0.39) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887317 0.78 ALOX5 (0.39) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL4154641 0.77 CYP2D6 (0.41) RAB9ASMN1; SMN2HPGDALKBH3
SCHEMBL5887556 0.76 ALOX5 (0.40) NPC1RAB9ASMN1; SMN2HPGDHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R NPC1 1831/4885RAB9A 1054/4885SMN1; SMN2 1459/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R NPC1 2930/4885RAB9A 1724/4885SMN1; SMN2 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.